Nasdaq

SCYNEXIS, Inc. Advances Phase 1 Trial of SCY-247 Antifungal and Prepares for Phase 3 MARIO Study Restart

SCYNEXIS, Inc. is progressing on its second-generation antifungal SCY-247, having initiated a Phase 1 trial in December 2024, with results expected in Q3 2025. The company also plans to present data ...
Nasdaq

Vigil Neuroscience, Inc. Reports Positive Phase 1 Data for VG-3927 and Outlines Upcoming Milestones in Alzheimer’s Disease and ALSP Treatment Programs

Vigil Neuroscience reported positive Phase 1 trial results for VG-3927 and plans a Phase 2 trial in Q3 2025. Vigil Neuroscience, Inc. announced promising outcomes from a Phase 1 clinical trial of ...
Seeking Alpha

Celcuity Inc. (CELC) Discusses Additional Results From Phase III VIKTORIA-1 Trial and Insights Into PAM Pathway Targeting Transcript

Hello, and thank you for standing by. My name is Bella, and I will be your conference operator today. At this time, I would like to welcome everyone to Phase III VIKTORIA-1 Additional Results ...